Axonal pathology in multiple sclerosis: Relationship to neurologic disability

Current Opinion in Neurology

Volumn 12, Issue 3, 1999, Pages 295-302

  Trapp, Bruce D ^a   Ransohoff, Richard ^a   Rudick, Richard ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; NEUROPROTECTIVE AGENT;

BRAIN ATROPHY; DEMYELINATING DISEASE; DISEASE COURSE; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; REVIEW;

EID: 0032796747     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199906000-00008     Document Type: Review

References (49)

1. Charcot M. Histology of the sclerotic plaque [in french]. Gaz Hosp 1868; 141:554-558.
2. Marburg O. Acute multiple sclerosis (encephalomyelitis periaxialis scleroticans) [in German]. Jahrbücher Für Psychiatrie und Neurologie 1906; 27:213-312.
3. Putnam TJ. Studies in multiple sclerosis. Arch Neurol Psychiatry 1936; 35:1289-1308.
4. Greenfield JG, King LS. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 1936; 59:445-458.
5. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acutemultiple sclerosis lesions. Brain 1997; 120:393-399. This paper correlates axonal pathology and axonal swellings with inflammation in multiple sclerosis brains and provides evidence that antegrade axonal transport is acutely altered after demyelination.
6. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87:1561-1565.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285. This paper described transected axons in multiple sclerosis lesions. Axonal transection correlated with inflammatory activity and was present in lesions from patients with clinical disease course of 2 weeks to 27 years.
8. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast- enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.
9. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997; 41:385-391. MRS imaging data in 28 multiple sclerosis patients and healthy control individuals is presented. The neuronal marker NAA was lower in multiple sclerosis patients both in lesions and in nonlesional white matter, suggesting that axonat loss or dysfunction extends beyond the inflammatory lesions.
10. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119:715-722.
11. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995; 64:742-748.
12. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36:76-82.
13. Bruhn H, Frahm J, Merboldt KD, Hanicke W, Hanefeld F, Christen HJ, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992; 32:140-150. This is an MRS study in eight children with multiple sclerosis, aged 7 to 16 years.
14. Simon JH, Schiffer RB, Rudick RA, Herndon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. Am J Neuroradiol 1987; 8:599-604.
15. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119:701-708.
16. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996; 119:2009-2019.
17. Simon JH, Jacobs LD, Campion M, Rudick RA, Cookfair DL, Herndon RM, et al. A longitudinal study of brain atrophy in relapsing MS. Neurology 1999 (in press).
18. Rudick RA, Fisher E, Lee J-C, Simon J, Miller D, Jacobs L, and the Multiple Sclerosis Collaborative Research Group. The effect of Avonex (IFNβ-1a) on cerebral atrophy in relapsing multiple sclerosis [abstract]. Neurology 1999; 52:A289-290.
19. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32:758-766.
20. McDonald WI. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 1994, 53:338-343.
21. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5:48-57.
22. Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998;4:55-62. This paper described axonal loss (up to 82%) in multiple sclerosis lesions from 11 individuals with clinically silent multiple sclerosis. These individuals had no reported neurologic symptoms during their lifetimes. The lack of neurologic symptoms were attributed to the following: most lesions were in clinically silent areas; low levels of total axonal loss; neuronal redundancy of affected areas; and remyelination.
23. Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve 1998; 10:490-502.
24. Lloyd KG. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol 1977; 90:255-266.
25. Yin X, Crawford TO, Griffin JW, Tu Ph, Lee VM, Li C, et al. Myelin-associate glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998; 18:1953-1962. This paper described axonal degeneration in mice that lack the myelin-associated glycoprotein. These mice myelinate normally and develop late-onset axonal pathology and degeneration. These observations support the hypothesis that myelin provides external trophic signals to axons. Loss of this trophic effect in multiple sclerosis may lead to degeneration of chronically demyelinated axons.
26. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 98: 610-1613. This paper describes axonal degeneration in mice that lack proteolipid protein. These mice form normal amounts of myelin membrane and begin to develop axonal swellings at 6-8 weeks of age. By 12 months of age, axonal degeneration in the absence of primary demyelination occurs in fiber tracts with axonal swellings. These data support the possibility that chronic demyelination in multiple sclerosis can lead to axonal degeneration.
27. Bradley WG, BDNF Study Group. Recombinant methionyl human brain-derived neuronotrophic factor (r-met HuBDNF) in the treatment of patients with amyotrophic lateral sclerosis. Ann Neurol 1999 (in press).
28. ALS CNTF Treatment Study (ACTS Study Group). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human cilliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46:1244-1249.
29. Miller RG, Petajan J, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, et al. A placebo-controlled trial of recombinant human ciliary neuronotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996; 39:256-260.
30. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. Neurology 1998; 51:583-586.
31. Lai EC, Felice KJ, Gawel MJ, Gelinas DF, Kraz R, Murphy MF, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. Neurology 1997; 49:1621-1630.
32. Cedarbaum JM, Stambler N, Brooks BR, Bradley WG. Brain-derived neuronotrophic factor in ALS: a failed drug or failed trials. Ann Neurol 1998; 44:506-507.
33. Sabatini DM, Lai MM, Snyder SH. Neural roles of immunophilins and their ligands. Mol Neurobiol 1997; 15:223-239.
34. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA 1994; 91:3191-3195.
35. Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson TM, Hester L, Snyder SH. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Med 1997; 3:421-428.
36. Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci 1994; 6:287-296.
37. Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 1995; 15:7509-7516.
38. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H, Connolly MA, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94:2019-2024.
39. Prineas JW, McDonald WI. Demyelinating diseases. In: Greenfield's neuropathology. 6th ed. Graham DI, Lantos PL (editors). New York: Oxford University Press; 1997. pp. 813-896.
40. Raine CS, Scheinberg I, Waltz JM. Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 1981; 45:534-546.
41. Prineas JW, Kwon EE, Goldenberg PZ. Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 1989; 61:489-503.
42. Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 1997; 19:197-203.
43. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983; 303:390-396.
44. Wolswijk G, Noble M. Identification of an adult-specific glial progenitor cell. Development 1989; 105:387-400.
45. Levine JM, Stincone F, Lee YS. Development and differentiation of glial precursor cells in the rat cerebellum. Glia 1993; 7:307-321.
46. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res 1996; 43:299-314.
47. Nishiyama A, Yu M, Drazba JA, Tuohy VK. Normal and reactive NG2+ glial cells are distinct from resting and activated microglia. J Neurosci Res 1997; 48:299-312. This paper describes the 'distribution and characteristics of oligodendrocytes progenitor cells in the adult brain'. These cells appear to be as abundant as astrocytes, and they are clearly distinct from mature oligodendrocytes, astrocytes, and microglia.
48. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18:601-609.
49. Duncan ID, Grever WE, Zhang SC. Repair of myelin disease: strategies and progress in animal models. Mol Med Today 1997; 97:554-561. This review nicely summarizes the current state of transplantation research as it applies to myelin disease.